Annals of Surgical Oncology

, Volume 19, Issue 5, pp 1678–1684 | Cite as

Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy

  • George W. Dittrick
  • Jill M Weber
  • Ravi Shridhar
  • Sarah Hoffe
  • Marcovalerio Melis
  • Khaldoun Almhanna
  • James Barthel
  • James McLoughlin
  • Richard C. Karl
  • Kenneth L. Meredith
Thoracic Oncology

Abstract

Background

Neoadjuvant chemoradiation (NCRT) has become the preferred treatment for patients with locally advanced esophageal cancer. Survival often is correlated to degree of pathologic response; however, outcomes in patients who are found to be pathologic nonresponders (pNR) remain uninvestigated. This study was designed to evaluate survival in pNR to NCRT compared with patients treated with primary esophagectomy (PE).

Methods

Using our comprehensive esophageal cancer database, we identified patients treated with NCRT and deemed pNR along with patients who proceeded to PE. Clinical and pathologic data were compared using Fisher’s exact and χ2, whereas Kaplan–Meier estimates were used for survival analysis.

Results

We identified 63 patients treated with NCRT and were found to have a pNR, and 81 patients who underwent PE. Disease-free (DFS) and overall survival (OS) were significantly decreased in the pNR group compared with those treated with PE (10 vs. 50 months (0–152), P < 0.001 and 13 vs. 50 months (0–152), P < 0.001, respectively). For patients with stage II disease, DFS and OS were similarly decreased in pathologic nonresponders (13 vs. 62 months (0–120), P < 0.001 and 31 vs. 62 months (0–120), P = 0.024, respectively). There were no differences in DFS or OS for patients with stage III disease (10 vs. 14 months (0–152), P = 0.29 and 10 vs. 19 months (0–152), P = 0.16, respectively).

Conclusions

Pathologic nonresponders to NCRT for esophageal cancer receive no benefit in DFS or OS compared with patients treated with PE. For patients with stage II disease, DFS and OS are, in fact, significantly decreased in the pNR.

Keywords

Overall Survival Esophageal Cancer Median Overall Survival National Comprehensive Cancer Network National Comprehensive Cancer Network 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):22549.PubMedCrossRefGoogle Scholar
  2. 2.
    Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67(6):38190.Google Scholar
  3. 3.
    Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77(8):84557.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu PC, Posner MC, Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):4818.PubMedCrossRefGoogle Scholar
  5. 5.
    Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):70716.PubMedCrossRefGoogle Scholar
  6. 6.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [see comment]. N Engl J Med. 2006;355(1):1120.PubMedCrossRefGoogle Scholar
  7. 7.
    Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):1617.PubMedCrossRefGoogle Scholar
  8. 8.
    Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [see comment]. Lancet Oncol. 2005;6(9):65968.PubMedCrossRefGoogle Scholar
  9. 9.
    Gebski V, Burmeister B, Smithers BM, et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [see comment]. Lancet Oncol. 8(3): 22634.PubMedCrossRefGoogle Scholar
  10. 10.
    Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60(2):42736.PubMedCrossRefGoogle Scholar
  11. 11.
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer [see comment]. N Engl J Med. 1998;339(27):197984.PubMedCrossRefGoogle Scholar
  12. 12.
    Naughton P, Walsh TN, Naughton P, Walsh TN. Preoperative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer. Cancer Treat Rev. 2004;30(1):1414.PubMedCrossRefGoogle Scholar
  13. 13.
    Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):19306; discussion 19367.Google Scholar
  14. 14.
    Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15(2):1214.PubMedCrossRefGoogle Scholar
  15. 15.
    Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104(11):236572.PubMedCrossRefGoogle Scholar
  16. 16.
    Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma [see comment]. J Clin Oncol. 2001;19(2):30513.PubMedGoogle Scholar
  17. 17.
    Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comment] [erratum appears in N Engl J Med 1999;341(5):384]. N Engl J Med. 1996;335(7):4627.PubMedCrossRefGoogle Scholar
  18. 18.
    Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):115967.PubMedCrossRefGoogle Scholar
  19. 19.
    Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):134755.PubMedCrossRefGoogle Scholar
  20. 20.
    Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11): 26806.PubMedCrossRefGoogle Scholar
  21. 21.
    Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival [see comment]. J Clin Oncol. 2003;21(21):400915.PubMedCrossRefGoogle Scholar
  22. 22.
    Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64(3):7659.PubMedCrossRefGoogle Scholar
  23. 23.
    McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg. 2008;206(5):87986; discussion 8867.Google Scholar
  24. 24.
    Aguirre ACR, Ramos-Font C, Portero RV, Cook GJR, Elvira JML, Tabares AR. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer systematic review of the literature. Ann Surg. 2009;250(2):24754.CrossRefGoogle Scholar
  25. 25.
    Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009;249(5):7647.PubMedCrossRefGoogle Scholar
  26. 26.
    Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6):9028.PubMedCrossRefGoogle Scholar
  27. 27.
    Schauer M, Janssen KP, Rimkus C, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010;16(1):3307.PubMedCrossRefGoogle Scholar
  28. 28.
    Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009;250(5):72937.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • George W. Dittrick
    • 1
  • Jill M Weber
    • 1
  • Ravi Shridhar
    • 2
  • Sarah Hoffe
    • 2
  • Marcovalerio Melis
    • 3
  • Khaldoun Almhanna
    • 1
  • James Barthel
    • 2
  • James McLoughlin
    • 4
  • Richard C. Karl
    • 1
  • Kenneth L. Meredith
    • 1
    • 5
  1. 1.Department of Gastrointestinal OncologyMoffitt Cancer CenterTampaUSA
  2. 2.Department of Radiation OncologyMoffitt Cancer CenterTampaUSA
  3. 3.Department of SurgeryNew York Presbyterian Veterans AdministrationNew YorkUSA
  4. 4.Department of SurgeryMedical College of GeorgiaAugustaUSA
  5. 5.Section Head of Esophagogastric OncologyH. Lee Moffitt Cancer and Research InstituteTampaUSA

Personalised recommendations